Literature DB >> 27559007

Risk factors for recurrence of borderline ovarian tumours: A tertiary centre experience.

Fuat Demirkiran1, Veysel Sal1, Tugan Bese1, Nedim Tokgozoglu1, Hakan Erenel2, Nigar Sofiyeva1, Ilker Kahramanoglu1, Macit Arvas1.   

Abstract

The aim of this study was to evaluate the risk factors for recurrence of borderline ovarian tumours. This study investigated 127 women who were finally diagnosed with borderline epithelial ovarian tumours. Most of them were diagnosed in stage I (83.4%). With a median follow-up of 81.8 months (range: 14-205), the median time to recurrence was 22.4 months (range: 3-74). Five-year recurrence-free survival (RFS) and overall survival (OS) rates were 85.8% and 97.6%, respectively. In multivariate analysis, invasive implants and fertility-sparing surgery were found to be independent prognostic factors for 5-year RFS. Overall, 20 patients (15.7%) experienced relapse within the observation period. Although there is no consensus about high-risk category of borderline ovarian tumours, invasive implants and conservative surgery were closely related to the recurrence. Patients presenting these risk factors should undergo closer follow-up.

Entities:  

Keywords:  Borderline; ovarian; prognostic factors; recurrence; surgery

Mesh:

Year:  2016        PMID: 27559007     DOI: 10.1080/01443615.2016.1188276

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  3 in total

1.  Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies.

Authors:  Angrit Stachs; Steffi Hartmann; Bernd Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-08-24       Impact factor: 2.915

2.  The safety of fertility and ipsilateral ovary procedures for borderline ovarian tumors.

Authors:  Tong Lou; Fang Yuan; Ying Feng; Shuzhen Wang; Huimin Bai; Zhenyu Zhang
Journal:  Oncotarget       Date:  2017-12-06

Review 3.  The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.

Authors:  Yu Sun; Juan Xu; Xuemei Jia
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.